TR200102733T2 - IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri - Google Patents

IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri

Info

Publication number
TR200102733T2
TR200102733T2 TR2001/02733T TR200102733T TR200102733T2 TR 200102733 T2 TR200102733 T2 TR 200102733T2 TR 2001/02733 T TR2001/02733 T TR 2001/02733T TR 200102733 T TR200102733 T TR 200102733T TR 200102733 T2 TR200102733 T2 TR 200102733T2
Authority
TR
Turkey
Prior art keywords
treatment
recombinant
related disorders
antagonists useful
mabs
Prior art date
Application number
TR2001/02733T
Other languages
English (en)
Inventor
D. Holmes Stephen
Sen Ho Yen
Harrison Taylor Alexander
S. Abdel-Meguid Sherin
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of TR200102733T2 publication Critical patent/TR200102733T2/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Kimerik, hümanize ve diger IL-18 mAb'ler, yüksek afiniteli nötrleyici mAb'lerden türetilmis olup, bunlari içeren farmasötik terkipler, tedavi ve teshis yöntemleri saglanmaktadir.
TR2001/02733T 1999-03-19 2000-03-17 IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri TR200102733T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12529999P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
TR200102733T2 true TR200102733T2 (tr) 2002-04-22

Family

ID=22419067

Family Applications (3)

Application Number Title Priority Date Filing Date
TR2001/02733T TR200102733T2 (tr) 1999-03-19 2000-03-17 IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
TR2002/02254T TR200202254T2 (tr) 1999-03-19 2000-03-17 IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
TR2002/02253T TR200202253T2 (tr) 1999-03-19 2000-03-17 IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri

Family Applications After (2)

Application Number Title Priority Date Filing Date
TR2002/02254T TR200202254T2 (tr) 1999-03-19 2000-03-17 IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
TR2002/02253T TR200202253T2 (tr) 1999-03-19 2000-03-17 IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri

Country Status (28)

Country Link
US (2) US6706487B1 (tr)
EP (2) EP1163271B1 (tr)
JP (1) JP2002542769A (tr)
KR (1) KR100697120B1 (tr)
CN (1) CN1246335C (tr)
AR (1) AR022952A1 (tr)
AT (1) ATE402191T1 (tr)
AU (1) AU764622B2 (tr)
BR (1) BR0008688A (tr)
CA (1) CA2368965C (tr)
CO (1) CO5470287A1 (tr)
CY (1) CY1108387T1 (tr)
CZ (1) CZ303704B6 (tr)
DE (1) DE60039589D1 (tr)
DK (1) DK1163271T3 (tr)
ES (1) ES2308974T3 (tr)
HK (1) HK1043798B (tr)
HU (1) HU228931B1 (tr)
IL (1) IL144995A0 (tr)
MY (1) MY124219A (tr)
NO (1) NO330391B1 (tr)
NZ (1) NZ513699A (tr)
PL (1) PL202396B1 (tr)
PT (1) PT1163271E (tr)
SI (1) SI1163271T1 (tr)
TR (3) TR200102733T2 (tr)
WO (1) WO2000056771A1 (tr)
ZA (1) ZA200107639B (tr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852266A (en) * 1993-07-14 1998-12-22 Hitachi, Ltd. Vacuum circuit breaker as well as vacuum valve and electric contact used in same
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
DK1265928T3 (da) * 2000-01-27 2010-11-15 Medimmune Llc RSV-neutraliserende antistoffer med ultra høj affinitet
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2003083071A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2002343870A1 (en) 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
AU2004235595C1 (en) 2003-04-30 2009-09-24 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
AU2011224023C1 (en) * 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Il-13에 대항한 인간 항체 및 치료적 용도
BRPI0711908B8 (pt) * 2006-05-25 2021-05-25 Glaxo Group Ltd anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
GB0610438D0 (en) * 2006-05-25 2006-07-05 Glaxo Group Ltd Immunoglobulins
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008312802A1 (en) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to abeta oligomer, and use thereof
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
PT2246427T (pt) * 2008-02-08 2017-03-03 Immunas Pharma Inc Anticorpos capazes de se ligar especificamente a oligómeros beta amilóides e a sua utilização
WO2009127046A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
WO2010020593A1 (en) * 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US8168165B2 (en) 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
ES2641612T3 (es) 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
KR20120034068A (ko) * 2009-06-30 2012-04-09 가부시키가이샤 고센 라켓용 스트링과 그 제조 방법 및 이것을 장설한 라켓
CN102574915B (zh) 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
JP5599454B2 (ja) 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Aβオリゴマーに特異的に結合する抗体およびその利用
EP3029070A1 (en) 2009-08-29 2016-06-08 AbbVie Inc. Therapeutic dll4 binding proteins
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
MX2012009167A (es) * 2010-02-09 2012-08-23 Glaxo Group Ltd Tratamiento de un trastorno metabolico.
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
EP3680253A3 (en) * 2010-03-02 2020-09-30 AbbVie Inc. Therapeutic dll4 binding proteins
US20130109107A1 (en) * 2010-05-25 2013-05-02 The Regents Of The University Of Colorado Diagnosis and treatment of autoimmune disease
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
CA2822515C (en) 2010-12-20 2023-04-25 Medimmune Limited Anti-il-18 antibodies and their uses
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP2924117B1 (en) 2012-11-21 2019-08-14 KM Biologics Co., Ltd. Novel human antibody against il-18
US10882905B2 (en) * 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
CA3183242A1 (en) * 2020-06-18 2021-12-23 Dallas Benjamin Flies Compositions and methods for modulating flrt3 mediated signal transduction
EP4371573A1 (en) 2021-07-13 2024-05-22 National University Corporation Tokai National Higher Education and Research System Medicinal composition for treating inflammatory bowel disease
CN117986360B (zh) * 2024-02-01 2024-08-27 生物岛实验室 Il18蛋白的特异性抗体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0528767B1 (en) 1991-08-21 2000-01-12 Novartis AG Antibody derivatives
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
FR2767697B1 (fr) 1997-09-01 2000-05-05 Boots Co Plc Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL

Also Published As

Publication number Publication date
CN1246335C (zh) 2006-03-22
ES2308974T3 (es) 2008-12-16
NO20014524L (no) 2001-11-14
CO5470287A1 (es) 2004-12-30
DE60039589D1 (de) 2008-09-04
PL350460A1 (en) 2002-12-16
EP1163271A4 (en) 2003-04-09
NO330391B1 (no) 2011-04-04
CY1108387T1 (el) 2014-02-12
AU764622B2 (en) 2003-08-28
AU3901600A (en) 2000-10-09
NO20014524D0 (no) 2001-09-18
EP1163271B1 (en) 2008-07-23
PT1163271E (pt) 2008-09-16
IL144995A0 (en) 2002-06-30
NZ513699A (en) 2004-02-27
WO2000056771A1 (en) 2000-09-28
BR0008688A (pt) 2002-01-08
CN1352650A (zh) 2002-06-05
DK1163271T3 (da) 2008-11-10
PL202396B1 (pl) 2009-06-30
TR200202253T2 (tr) 2002-12-23
CA2368965A1 (en) 2000-09-28
CA2368965C (en) 2010-05-18
ATE402191T1 (de) 2008-08-15
EP1163271A1 (en) 2001-12-19
HK1043798B (zh) 2009-04-09
HUP0200502A2 (en) 2002-06-29
US6706487B1 (en) 2004-03-16
HK1043798A1 (en) 2002-09-27
US20040141964A1 (en) 2004-07-22
KR100697120B1 (ko) 2007-03-20
HU228931B1 (en) 2013-06-28
JP2002542769A (ja) 2002-12-17
AR022952A1 (es) 2002-09-04
HUP0200502A3 (en) 2003-12-29
EP1961768A1 (en) 2008-08-27
TR200202254T2 (tr) 2002-12-23
CZ20013362A3 (cs) 2002-03-13
CZ303704B6 (cs) 2013-03-27
KR20020008130A (ko) 2002-01-29
ZA200107639B (en) 2002-09-17
MY124219A (en) 2006-06-30
SI1163271T1 (sl) 2008-10-31

Similar Documents

Publication Publication Date Title
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
EP1470146B8 (en) Antibodies against the muc18 antigen
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
RS80704A (en) ANTI- av?6.ANTIBODIES
HUP0303952A2 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
DE60141043D1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
DE69934515D1 (de) Humanisierte monoklonale integrin antikörper
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
WO2004031105A3 (en) Use of a33 antigens and jam-it
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
WO2001072334A3 (en) Methods for treating disease with antibodies to cxcr3
WO2005058358A3 (en) Use of agents derived from ceacam1 for the treatment of inflammatory diseases
WO2003087841A3 (en) An ephrin-b receptor protein involved in carcinoma
DE59911103D1 (de) ISOLIERTE UND GEREINIGTE HUMANE LÖSLICHE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGC ALPHA1/BETA1)
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases